‹ ›
MYP_132385
← PREVIOUS NEXT → BACK
Basic Information
P2shortA
Anticancer
Standard
16 amino acids
C76H139N25O21
Standard
Sequence
ALPISTVRSVALSRRL
Physicochemical Analysis
1739.07 Da
12.00
2.80
2.61
0.1747
0.61
0.38
-0.01
96.71
146.25
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
757.65
-8.14
29.0
24.0
56.0
122.0
1.0
15.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0235256 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
hydrocarbon-stapled side-chain cyclic peptide [Cyclic]
noncanonical stereochemical modification [Modified]
None
Amidation
Stapled: Ⓧ(9) and Ⓧ (13) are cross-linked by hydrocarbon stapling
Bio-Activity Profile
Anticancer
NCI-H358
10 μM
98% Killing
PaperBouclier C, Simon M, Laconde G, Pellerano M, Diot S, Lantuejoul S, Busser B, Vanwonterghem L, Vollaire J, Josserand V, Legrand B, Coll JL, Amblard M, Hurbin A, Morris MC. Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. Theranostics. 2020 Jan 12;10(5):2008-2028. PMID32104498 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32104498/
RECORD: Rec_0342764 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
hydrocarbon-stapled side-chain cyclic peptide [Cyclic]
noncanonical stereochemical modification [Modified]
None
Amidation
Stapled: Ⓧ(9) and Ⓧ (13) are cross-linked by hydrocarbon stapling
Bio-Activity Profile
Anticancer
PC-9
10 μM
80% Killing
PaperBouclier C, Simon M, Laconde G, Pellerano M, Diot S, Lantuejoul S, Busser B, Vanwonterghem L, Vollaire J, Josserand V, Legrand B, Coll JL, Amblard M, Hurbin A, Morris MC. Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. Theranostics. 2020 Jan 12;10(5):2008-2028. PMID32104498 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32104498/
RECORD: Rec_0343358 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
hydrocarbon-stapled side-chain cyclic peptide [Cyclic]
noncanonical stereochemical modification [Modified]
None
Amidation
Stapled: Ⓧ(9) and Ⓧ (13) are cross-linked by hydrocarbon stapling
Bio-Activity Profile
Anticancer
A549
10 μM
50% Killing
PaperBouclier C, Simon M, Laconde G, Pellerano M, Diot S, Lantuejoul S, Busser B, Vanwonterghem L, Vollaire J, Josserand V, Legrand B, Coll JL, Amblard M, Hurbin A, Morris MC. Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. Theranostics. 2020 Jan 12;10(5):2008-2028. PMID32104498 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32104498/